A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients Undergoing Oesophagectomy Surgery
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs GSK 2862277 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 08 Nov 2017 Status changed from recruiting to discontinued.
- 23 Feb 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.